At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
JNJ-42165279 +1 moredrug
Likely dose
JNJ-42165279 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects With Autism Spectrum Disorder
In Brief
A Phase 2 clinical trial evaluating JNJ-42165279 and Placebo for Autism Spectrum Disorder. Completed, enrolled 78 participants across 9 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy of JNJ-42165279 compared with placebo in the improvement of symptoms of Autism Spectrum Disorder (ASD) during 12 weeks of treatment using the Autism Behavior Inventory (ABI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionOct 2022
Study CompletionOct 2022
TodayJul 2026
First PostedSep 10, 2018
Enrollment StartNov 7, 2018
Primary CompletionOct 17, 2022
Study CompletionOct 28, 2022
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.8 years ago
Interventions
JNJ-42165279drug
Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
Placebodrug
Participants will receive a matching placebo orally twice daily for 12 weeks.